Meperidine (Demerol) Market to surpass US$ 2,784.3 Mn by 2027 - Coherent Market Insights

Global Meperidine (Demerol) Market, by Dosage Form (Tablets, Injection, and Syrup), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,089.1 Mn in 2020 and is expected to increase to US$ 2,784.3 Mn by 2027, witnessing a CAGR of 4.2% during the forecast period (2020-2027) as highlighted in a new report published by Coherent Market Insights.

Manufacturers are engaged in developing new meperidine (Demerol) products for pain management, which has led to an increase in product launches and approvals. This is expected to boost the global meperidine (Demerol) market growth. For instance, in 2015, Epic Pharma, launched generic meperidine in the U.S. for the relief of moderate to severe pain in 50-mg and 100-mg dosage strengths in 100 count bottles. Moreover, manufacturers such as Pfizer, Inc., Hikma Pharmaceuticals, and others also offer branded as well as generic meperidine in the market.

Browse 24 Market Data Tables, and 26 Figures spread through 140 Pages and in-depth TOC on Global Meperidine (Demerol) Market, by Dosage Form (Tablets, Injection, and Syrup), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027

To know the latest trends and insights prevalent in the meperidine (Demerol) market, click the link below:

https://www.coherentmarketinsights.com/market-insight/meperidine-market-3816

The rising prevalence of chronic diseases such as cancer and pain associated diseases is expected to result in higher use of potent opioid medications for pain management. Moreover, meperidine is used as a drug for post-operative pain. Meperidine has advantages such as providing very short analgesia which is appropriate for minimally invasive surgeries. Moreover, the growing preference for minimally invasive surgeries is also expected to support growth of the market during the forecast period. For instance, according a study published in January 2020 in Jama Network (The Journal of the American Medical Association), the use of robotic surgeries for all procedures had increased from 1.8% to 15.1% from 2012 to 2018 in the U.S. These factors are expected to support global meperidine (Demerol) market growth during the forecast period.

Key takeaways of the global meperidine (Demerol) market:

• The global meperidine (Demerol) market is expected to exhibit a CAGR of 4.2% during the forecast period (2020-2027) owing to product approvals and launches as well as increasing prevalence of chronic diseases requiring surgical intervention.
• On the basis of dosage form, the injection segment is expected to hold a dominant position in the global meperidine (Demerol) market during the forecast period owing to high use in post-operative pain management and post pregnancy pain management.
• Based on distribution channel, the hospital pharmacies segment is expected to witness significant growth due to increasing use of meperidine in post-operative pain management as it would be sold through hospital pharmacies.
• Some of the major players involved in the global meperidine (Demerol) market are Pfizer, Inc., Hikma Pharmaceuticals USA Inc., Epic Pharma, Inc., and Vintage Pharmaceuticals, Inc.